檢索結果 - Santos Carvajal‐Gonzalez

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Pharmacokinetics and pharmacodynamics of PF‐05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects

    Pharmacokinetics and pharmacodynamics of PF‐05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects 由 William S. Denney, Gabriele E. Sonnenberg, Santos Carvajal‐Gonzalez, Theresa Tuthill, V. Margaret Jackson

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study 由 Arthur Bergman, Santos Carvajal‐Gonzalez, Sanela Tarabar, Aditi R. Saxena, William P. Esler, Neeta B. Amin

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis

    Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis 由 Neeta B. Amin, Santos Carvajal‐Gonzalez, Julie J. Purkal, Tong Zhu, Collin Crowley, Sylvie Perez, Kristin Chidsey, Albert M. Kim, Bryan Goodwin

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems

    Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems 由 Trenton T. Ross, Collin Crowley, Kenneth L. Kelly, Anthony Rinaldi, David A. Beebe, Matthew P. Lech, Robert V. Martinez, Santos Carvajal‐Gonzalez, Magalie Boucher, Dinesh Hirenallur‐Shanthappa, Jeffrey Morin, Alan Opsahl, Sarah Regina Vargas, Kendra K. Bence, Jeffrey A. Pfefferkorn, William P. Esler

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes

    Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes 由 David A. Griffith, Daniel W. Kung, William P. Esler, Paul A. Amor, Scott W. Bagley, Carine Beysen, Santos Carvajal‐Gonzalez, Shawn D. Doran, Chris Limberakis, Alan M. Mathiowetz, Kirk McPherson, David A. Price, Éric Ravussin, Gabriele E. Sonnenberg, James A. Southers, Laurel J. Sweet, Scott Turner, F.F. Vajdos

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: